ACCESS Newswire (Tue, 25-Aug 7:00 AM ET)
PAPZIMEOS Drives Precigen to Profitability as Revenue More Than Doubles: What the Numbers Reveal
Market Chameleon (Wed, 5-Aug 7:11 AM ET)
PGEN Achieves Profitability on Accelerating PAPZIMEOS Revenue and Expands US Market Reach
Market Chameleon (Wed, 5-Aug 3:36 AM ET)
PRNewswire (Tue, 4-Aug 4:01 PM ET)
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
PRNewswire (Tue, 21-Jul 8:01 AM ET)
Market Chameleon (Thu, 14-May 6:16 AM ET)
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen trades on the NASDAQ stock market under the symbol PGEN.
As of September 17, 2026, PGEN stock price climbed to $7.87 with 5,422,478 million shares trading.
PGEN has a beta of 0.89, meaning it tends to be less sensitive to market movements. PGEN has a correlation of 0.02 to the broad based SPY ETF.
PGEN has a market cap of $2.82 billion. This is considered a Mid Cap stock.
Last quarter Precigen reported $55 million in Revenue and $.05 earnings per share. This beat revenue expectation by $27 million and exceeded earnings estimates by $.06.
In the last 3 years, PGEN traded as high as $7.95 and as low as $.65.
The top ETF exchange traded funds that PGEN belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
PGEN has outperformed the market in the last year with a price return of +102.3% while the SPY ETF gained +16.7%. PGEN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +65.7% and +12.3%, respectively, while the SPY returned +1.9% and -0.3%, respectively.
PGEN support price is $7.18 and resistance is $7.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PGEN shares will trade within this expected range on the day.
